What was the overall market valuation for the growth hormone-deficiency market in 2024?

The overall market valuation for the growth hormone-deficiency market was 242.0 $ Million in 2024. Read More

What is the projected market valuation for 2035?

The projected market valuation for 2035 is 355.0 $ Million. Read More

What is the expected CAGR for the growth hormone-deficiency market during the forecast period 2025 - 2035?

The expected CAGR for the growth hormone-deficiency market during the forecast period 2025 - 2035 is 3.54%. Read More

Which companies are considered key players in the growth hormone-deficiency market?

Key players in the market include Pfizer, Eli Lilly, Novo Nordisk, Merck KGaA, Ipsen, Sandoz, Hikma Pharmaceuticals, and Ferring Pharmaceuticals. Read More

What are the leading brands in the growth hormone-deficiency market and their valuations?

Leading brands include Norditropin at 60.0 - 90.0 $ Million, Genotropin at 50.0 - 75.0 $ Million, and Humatrope at 40.0 - 60.0 $ Million. Read More

What applications are driving the growth hormone-deficiency market?

Applications driving the market include Adult Growth Hormone Deficiency at 60.0 - 85.0 $ Million and Paediatric Growth Hormone Deficiency at 40.0 - 60.0 $ Million. Read More

What routes of administration are most common in the growth hormone-deficiency market?

The most common routes of administration are Subcutaneous at 80.0 - 120.0 $ Million and Intravenous at 102.0 - 145.0 $ Million. Read More

How are growth hormone-deficiency products distributed in the market?

Distribution channels include Hospital Pharmacies at 60.0 - 90.0 $ Million and E-Commerce Websites at 62.0 - 90.0 $ Million. Read More

What is the market size for the application of Turner Syndrome?

The market size for the application of Turner Syndrome is projected to be between 20.0 - 30.0 $ Million. Read More

What is the valuation range for the application of Idiopathic Short Stature?

The valuation range for the application of Idiopathic Short Stature is between 30.0 - 45.0 $ Million. Read More

UK Growth Hormone Deficiency Market

UK Growth Hormone Deficiency Market Research Report: Size, Share, Trend Analysis By Applications (Pediatric Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Small for Gestational Age, Adult Growth Hormone Deficiency, Prader-Willi Syndrome, Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacy) and By Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, others) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.54%

2024 Market Size

$ 242 Million

2035 Market Size

$ 355 Million

Healthcare ● Updated April 2026 Report ID: MRFR/HC/48309-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Medical Device, BY Brand (USD Million)
  1. 4.1.1 Norditropin
  2. 4.1.2 Genotropin
  3. 4.1.3 Humatrope
  4. 4.1.4 Saizen
  5. 4.1.5 Omnitrope
  6. 4.1.6 Others
2. 4.2 Medical Device, BY Application (USD Million)
  1. 4.2.1 Paediatric Growth Hormone Deficiency
  2. 4.2.2 Idiopathic Short Stature
  3. 4.2.3 Small for Gestational Age
  4. 4.2.4 Turner Syndrome
  5. 4.2.5 Adult Growth Hormone Deficiency
  6. 4.2.6 Prader-Willi Syndrome
  7. 4.2.7 Others
3. 4.3 Medical Device, BY Route of Administration (USD Million)
  1. 4.3.1 Subcutaneous
  2. 4.3.2 Intramuscular
  3. 4.3.3 Intravenous
4. 4.4 Medical Device, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Clinics
  4. 4.4.4 E-Commerce Websites
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Medical Device
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novo Nordisk (DK)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Merck KGaA (DE)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ipsen (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sandoz (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Hikma Pharmaceuticals (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ferring Pharmaceuticals (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY BRAND
3. 6.3 UK MARKET ANALYSIS BY APPLICATION
4. 6.4 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF MEDICAL DEVICE
9. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
11. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
12. 6.12 MEDICAL DEVICE, BY BRAND, 2024 (% SHARE)
13. 6.13 MEDICAL DEVICE, BY BRAND, 2024 TO 2035 (USD Million)
14. 6.14 MEDICAL DEVICE, BY APPLICATION, 2024 (% SHARE)
15. 6.15 MEDICAL DEVICE, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 MEDICAL DEVICE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 MEDICAL DEVICE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY BRAND, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Growth Hormone Deficiency Market Segmentation

UK Growth Hormone Deficiency Market By Brand (USD Million, 2025-2035)

Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
Others

UK Growth Hormone Deficiency Market By Application (USD Million, 2025-2035)

Paediatric Growth Hormone Deficiency
Idiopathic Short Stature
Small for Gestational Age
Turner Syndrome
Adult Growth Hormone Deficiency
Prader-Willi Syndrome
Others

UK Growth Hormone Deficiency Market By Route of Administration (USD Million, 2025-2035)

Subcutaneous
Intramuscular
Intravenous

UK Growth Hormone Deficiency Market By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Clinics
E-Commerce Websites

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”